Coherus Warns Of US Pegfilgrastim Supply Gap In October

Udenyca Biosimilar To Neulasta Set For Interruption As Packaging CMO Is Overstretched

 
• By Dave Wallace

Coherus BioSciences has warned that a supply interruption is coming for its Udenyca biosimilar pegfilgrastim rival to Neulasta in the US, after a CMO used for final packaging revealed capacity constraints.

Mind The Gap sign on floor outside train door
A supply gap is expected for Udenyca starting in October • Source: Shutterstock

More from Biosimilars

More from Products